Rathmell: To improve funding outlook, we must reverse distrust in science

NCI renews MUSC Hollings support grant with “outstanding” rating

NCI has renewed MUSC Hollings Cancer Center’s five-year Cancer Center Support Grant, with an overall rating of “outstanding.”

April 19, 2024

Vol.50 No.16

Clinical

Pooled analysis questions reliability of an endpoint used in multi-cancer detection trials

An analysis by researchers from the International Agency for Research on Cancer casts doubt on validity of an endpoint used in key studies of multi-cancer detection tests.

NCI creates Cancer Equity Leaders group to improve cancer health equity

To address inequities in cancer health, NCI is collaborating with a diverse team of experts and cancer center directors—named the Cancer Equity Leaders (CEL)—to learn from communities and inform workforce development as well as outreach initiatives.

April 12, 2024

Vol.50 No.15

By Matthew Bin Han Ong

Funding Opportunities

DOD Lung Cancer Research Program funding opportunities for FY24

The FY24 Defense Appropriations Act provides funding for the LCRP to support innovative, high-impact lung cancer research. The managing agent for the anticipated funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command.

April 12, 2024

Vol.50 No.15

NCI maintains paylines for early-stage investigators, cuts funding for other R01s and noncompeting grants in FY24

NCI is lowering paylines for R01 grants for established and new investigators to the 10th percentile, down from the 12th percentile in FY23.

April 05, 2024

Vol.50 No.14

By Matthew Bin Han Ong

In Brief

Pfizer’s Albert Bourla to receive the AACR Outstanding Achievement Award for Service to Cancer Science and Medicine

Albert Bourla, Pfizer’s chairman and CEO, will receive the 2024 the American Association for Cancer Research Outstanding Achievement Award for Service to Cancer Science and Medicine during the AACR Annual Meeting 2024, to be held April 5-10 in San Diego, California.

April 05, 2024

Vol.50 No.14

Rathmell: To improve funding outlook, we must reverse distrust in science

YOU MAY BE INTERESTED IN

NCI renews MUSC Hollings support grant with “outstanding” rating

Pooled analysis questions reliability of an endpoint used in multi-cancer detection trials

NCI creates Cancer Equity Leaders group to improve cancer health equity

DOD Lung Cancer Research Program funding opportunities for FY24

NCI maintains paylines for early-stage investigators, cuts funding for other R01s and noncompeting grants in FY24

Pfizer’s Albert Bourla to receive the AACR Outstanding Achievement Award for Service to Cancer Science and Medicine

Renew today!

Subscriber content

Login